ArticleTechniques in coloproctology2026
Efficacy of botulinum toxin type A administration within the current therapeutic algorithm for chronic anal fissure: study protocol for the prospective multicentre observational study FISURBOT-GECO6.
Article in Techniques in coloproctology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic anal fissure is a common, benign anorectal condition associated with impaired quality of life. Despite the availability of several therapeutic options, considerable variability persists in its management, particularly regarding the role of botulinum toxin type A administration within the current treatment algorithms. Although botulinum toxin type A injection is a widely used approach to achieve chemical sphincterotomy, its real-world efficacy and safety across different clinical scenarios remain insufficiently characterised.
aimOur objective is to evaluate the efficacy and safety of botulinum toxin type A injection for the treatment of chronic anal fissure after failure of topical therapy or lateral internal sphincterotomy in routine clinical practice settings by analysing the healing rate, continence outcomes and the need for subsequent surgical intervention in predefined clinical scenarios.
methodsFISURBOT-GECO6 (0143-2024-OBS) is a national, multicentre, prospective, pragmatic observational study. Consecutive patients with chronic anal fissure in whom botulinum toxin treatment is recommended according to routine clinical practice are eligible. Patients will be classified into three clinical scenarios: (1) chronic anal fissure with sphincter hypertonia and no risk factors for anal incontinence after failure of topical therapy; (2) chronic anal fissure with recognised risk factors for anal incontinence after failure of topical therapy; and (3) chronic anal fissure persisting or recurring at least 12 weeks after lateral internal sphincterotomy. Botulinum toxin type A administered at a dose of 50 or 100 IU, according to routine practice. Patients will be evaluated at 1, 3 and 12 months after treatment. The primary outcome is clinical healing. Secondary outcomes are anal continence, procedure-related morbidity, need for repeat treatment or surgery and patient satisfaction. EXPECTED RELEVANCE: This study will provide prospective, real-world data on the efficacy and safety of botulinum toxin type A injection for chronic anal fissure management in clinically relevant scenarios. The results are expected to help clarify the role of this approach within current therapeutic algorithms and inform clinical decision-making in daily practice. TRIAL SPONSOR: Spanish Society of Coloproctology (AECP).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.